Casma Therapeutics
PrivateLast Round
Grant
Mar 10, 2026
Total Funding Raised
$162.47M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Casma Therapeutics is a biotechnology company that develops targeted therapies by harnessing the natural cellular process of autophagy to treat lysosomal storage, muscle, inflammatory, and neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Casma Therapeutics Comparables
Compare Casma Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lysoway Therapeutics | 90% | |
| Libra Therapeutics | 89% | |
| Nine Square Therapeutics | 88% | |
Casma Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 10, 2026 | ||||
| Series C | Nov 15, 2022 | ||||
| Series B | Sep 10, 2020 | ||||
| Grant | May 29, 2019 | ||||
| Series A | May 3, 2018 |
Casma Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series C, Series B |
| Mirae Asset | Series C |
| Schroder Adveq | Series B |
| Eventide Funds | Series C, Series B |
| The Chernin Group | Series C, Series B |
| Amgen Ventures | Series C |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2026
Secured $7.6M in grant funding.
- Jun 9, 2025
CSM-101 is in development for Parkinson's and Gaucher disease.
Casma Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Casma Therapeutics's valuation, stock price, and market status.